Language:

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry

PloS one, 2013-05, Vol.8 (5), p.e63479-e63479 [Peer Reviewed Journal]

COPYRIGHT 2013 Public Library of Science ;COPYRIGHT 2013 Public Library of Science ;2013 Kakkar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Kakkar et al 2013 Kakkar et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0063479 ;PMID: 23704912

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry
Author: Kakkar, Ajay K ; Mueller, Iris ; Bassand, Jean-Pierre ; Fitzmaurice, David A ; Goldhaber, Samuel Z ; Goto, Shinya ; Haas, Sylvia ; Hacke, Werner ; Lip, Gregory Y H ; Mantovani, Lorenzo G ; Turpie, Alexander G G ; van Eickels, Martin ; Misselwitz, Frank ; Rushton-Smith, Sophie ; Kayani, Gloria ; Wilkinson, Peter ; Verheugt, Freek W A
Hernandez, Adrian V.
Subjects: Adults ; Age ; Aged ; Anticoagulants ; Anticoagulants (Medicine) ; Atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - diagnosis ; Atrial Fibrillation - drug therapy ; Cardiac arrhythmia ; Cardiology ; Care and treatment ; Clinical medicine ; Contraindications ; Demographics ; Demography ; Diabetes ; Drugs ; Enrollments ; Ethics ; Female ; Fibrillation ; Fibrinolytic Agents - therapeutic use ; Health aspects ; Health risks ; Heart ; Hospitals ; Humans ; Hypertension ; Male ; Mathematics ; Medical research ; Medicine ; Medicine, Experimental ; Molecular Sequence Data ; Patients ; Prospective Studies ; Randomized Controlled Trials as Topic ; Registries ; Risk Factors ; Risk management ; Stroke ; Stroke (Disease) ; Stroke - drug therapy ; Stroke - etiology ; Therapy ; Thrombosis ; Vitamin K ; Vitamin K - antagonists & inhibitors
Is Part Of: PloS one, 2013-05, Vol.8 (5), p.e63479-e63479
Description: Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a worldwide perspective. The aim of this study was to describe the baseline characteristics and initial therapeutic management of patients with non-valvular atrial fibrillation across the spectrum of sites at which these patients are treated. The Global Anticoagulant Registry in the FIELD (GARFIELD) is an observational study of patients newly diagnosed with non-valvular atrial fibrillation. Enrollment into Cohort 1 (of 5) took place between December 2009 and October 2011 at 540 sites in 19 countries in Europe, Asia-Pacific, Central/South America, and Canada. Investigator sites are representative of the distribution of atrial fibrillation care settings in each country. Cohort 1 comprised 10,614 adults (≥18 years) diagnosed with non-valvular atrial fibrillation within the previous 6 weeks, with ≥1 investigator-defined stroke risk factor (not limited to those in existing risk-stratification schemes), and regardless of therapy. Data collected at baseline included demographics, medical history, care setting, nature of atrial fibrillation, and treatments initiated at diagnosis. The mean (SD) age of the population was 70.2 (11.2) years; 43.2% were women. Mean±SD CHADS2 score was 1.9±1.2, and 57.2% had a score ≥2. Mean CHA2DS2-VASc score was 3.2±1.6, and 8,957 (84.4%) had a score ≥2. Overall, 38.0% of patients with a CHADS2 score ≥2 did not receive anticoagulant therapy, whereas 42.5% of those at low risk (score 0) received anticoagulant therapy. These contemporary observational worldwide data on non-valvular atrial fibrillation, collected at the end of the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke. ClinicalTrials.gov TRI08888.
Publisher: United States: Public Library of Science
Language: English
Identifier: ISSN: 1932-6203
EISSN: 1932-6203
DOI: 10.1371/journal.pone.0063479
PMID: 23704912
Source: GFMER Free Medical Journals
MEDLINE
PubMed Central
Public Library of Science (PLoS)
ProQuest Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry

Searching Remote Databases, Please Wait